Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Indications and outcomes of uterine artery embolization in patients with uterine leiomyomas.

Hidenori Sasa | Tatsumi Kaji | Kenichi Furuya
Obstetrics and gynecology international | 2012

Objective. To investigate the indication and limitations of uterine artery embolization (UAE), we retrospectively analyzed the case of patients with uterine leiomyomas who had undergone UAE. Methods. During the past 7 years, 25 patients with uterine leiomyomas had undergone UAE in our hospital. UAE was indicated in patients with menstrual disturbances such as hypermenorrhea or dysmenorrhea. The outcomes of this procedure for uterine leiomyomas were analyzed. Results. Improvement in the menstrual symptoms and/or reduction in the leiomyoma size after UAE were observed in 24 patients (96.0%). There was mean 67.9% reduction in the volume of leiomyomas at six months after UAE (P < 0.05). However, the symptoms recurred after UAE in 6 patients (24.0%), with multiple or intramural leiomyomas larger than 7 cm, which necessitated additional procedures. Conclusion. The indications and limitations of the UAE should be considered because of its noneffectiveness and/or recurrence in over 20% of patients with uterine leiomyomas.

Pubmed ID: 22135681

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Pfizer Animal Genetics (tool)

RRID:SCR_008447

THIS RESOURCE IS NO LONGER IN SERVICE, documented on January 31, 2022. Data services to support validation of economically relevant traits for the livestock industries. Sponsors: This resource is supported by Pfizer Animal Health. Keywords: Animal, Genetics, Health, World, Genetic, Information, Service, Industry, Livestock, DNA, Maker, Technology, Phenotypic, Productivity,

View all literature mentions